Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare
The Ministry of Health, Labour and Welfare (MHLW) has approved Juluca Combination Tablets for the maintenance treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Read more -
GSK and Kyowa Hakko Kirin sign strategic commercialisation deal in Japan for daprodustat, a potential new oral treatment for anaemia associated with chronic kidney disease
Announcing a strategic collaboration for the future commercialisation of daprodustat in Japan.
Read more -
Access to Medicine Index 2018 media statement
GSK media statement on the results of the Access to Medicine Index 2018
Read more -
GSK submits US regulatory filing to expand the use of Nucala in children with severe eosinophilic asthma
Supplemental Biologics License Application (sBLA) filed to the US FDA seeking an additional indication for the use of Nucala (mepolizumab) as an add-on treatment for severe eosi...
Read more -
ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine
Committee for Medicinal Products for Human Use (CHMP) has adopted a Positive Opinion on a Type II variation regulatory application for Tivicay (dolutegravir).
Read more -
Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
Once-daily Trelegy Ellipta now available for COPD patients requiring a step up from dual bronchodilation
Read more -
Statement: GSK supports GOLD committee’s efforts to further personalise COPD management
Welcoming the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy.
Read more -
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV
BRIGHTE study highlights ViiV Healthcare’s commitment to developing innovative medicines for all people living with HIV, including those heavily-treated and failing on current a...
Read more -
GSK delivers Q3 sales of £8.1 billion, +3% AER, +6% CER
Total EPS 28.8p, +16% AER, +23% CER; Adjusted EPS 35.5p, +10% AER, + 14% CER
Read more -
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen
FLAIR study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen of cabotegravir and rilpivirine compared to a daily,...
Read more -
ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen
LATTE-2 study shows high rates of virologic response and long-term durability with the long-acting, injectable, two-drug regimen over 160 weeks
Read more -
GSK announces positive phase 3 results for daprodustat in patients with anaemia associated with chronic kidney disease
Second of three pivotal studies intended to support regulatory filing in Japan in 2019
Read more -
GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
Marked patient benefit observed in phase II study supports further clinical development of GSK3196165 for RA.
Read more -
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
Priority review voucher used with NDA submission with anticipated target action date of six months.
Read more -
GSK updates policy for working with healthcare professionals
We are updating our policy on working with healthcare professionals (HCPs).
Read more -
Positive results from Harmony Outcomes study of albiglutide published in The Lancet
GSK and the Duke Clinical Research Institute (DCRI) today announced publication of positive results from the Harmony Outcomes study which assessed the cardiovascular (CV) safety...
Read more -
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
Positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions
Read more -
GSK and Tres Cantos Open Lab Foundation announce additional £5m funding for open innovation research in diseases impacting the developing world
Additional £5m in GSK funding to support the Foundation’s research and development programmes in diseases of the developing world.
Read more -
Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone fu...
Read more -
Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria
Approval marks a major step in global eradication efforts and will support registrations in malaria-endemic countries
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
